Leerink initiated coverage of Maze Therapeutics (MAZE) with an Outperform rating and $28 price target Maze is a clinical-stage biotechnology company focused on leveraging human genetics to develop novel, small-molecule precision medicines across renal, cardiovascular, and related metabolic diseases, the analyst tells investors in a research note. The firm says the company is developing therapies in areas of significant unmet need and strategic interest, which should resonate favorably with investors. It believes the shares can move higher over the next 12 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics initiated with a Buy at TD Cowen
- Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics
- Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829
- Maze Therapeutics initiated with an Overweight at JPMorgan
- Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market